Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ensifentrine - Verona Pharma

Next Previous
X
Search
Drug Profile

Ensifentrine - Verona Pharma

Alternative Names: Ohtuvayre; RPL 554

Latest Information Update: 26 Aug 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Vernalis
  • Developer Verona Pharma
  • Class Anti-inflammatories; Antiallergics; Antiasthmatics; Antibronchitics; Antifibrotics; Imines; Isoquinolines; Small molecules; Urea compounds
  • Mechanism of Action Cystic fibrosis transmembrane conductance regulator stimulants; Type 3 cyclic nucleotide phosphodiesterase inhibitors; Type 4 cyclic nucleotide phosphodiesterase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Chronic obstructive pulmonary disease
  • Phase II Asthma; Bronchiectasis; Cystic fibrosis
  • Phase I Allergic asthma
  • Discontinued Allergic rhinitis; COVID 2019 infections

Most Recent Events

  • 19 Aug 2024 Verona Pharma plans a phase II trial for Bronchiectasis (Inhalation) in September 2024 (NCT06559150)
  • 08 Aug 2024 Launched for Chronic obstructive pulmonary disease in USA (Inhalation)
  • 26 Jun 2024 Verona Pharma announces intention to launch ensifentrine for Chronic obstructive pulmonary disease (Inhalation) in USA in third quarter of the 2024

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top